EC approves Roche’s Evrysdi for babies under two months with SMA
Betsy Goodfellow | August 30, 2023 | News story | Research and Development | European Commission, Evrysdi, Musculo-skeletal disorder, Roche, spinal muscular atrophy
Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing authorisation in the EU to include infants under two months with a clinical diagnosis of spinal muscular atrophy (SMA).
This extended authorisation follows interim data from the ongoing RAINBOWFISH trial assessing the drug for the treatment of pre-symptomatic babies from birth to six weeks with Type 1 SMA. The trial included six babies with two or three copies of the SMN2 gene, who completed at least a year of study assessments, all were able to sit after a year on Evrysdi, four could stand and three could walk independently.
The safety profile of the drug remained consistent with previous data, with the most common adverse reactions being fever, diarrhoea, rash, upper respiratory tract infection (including nasopharyngitis rhinitis), lower respiratory tract infection (including pneumonia, bronchitis), constipation, vomiting and cough.
Dr Nicole Gusset, president and CEO of SMA Europe, commented: “The SMA community welcomes the EC’s decision to extend the use of Evrysdi from birth. Preserving motor neurons from the earliest age possible and preventing their irreversible loss can have a substantial impact on a person’s future ability to move and function. We look forward to continued collaborative efforts to improve diagnosis, including newborn screening, and ensuring all individuals living with SMA have access to medicines.”
Levi Garraway, MD PhD, Roche’s chief medical officer and head of Global Product Development, added: “With this label extension, we can treat babies soon after birth with Evrysdi, allowing them the greatest chance to achieve the milestones of sitting, standing and walking, similar to healthy children.”
The drug was previously approved in the EU in March 2021 for patients over the age of two months.
Betsy Goodfellow
Related Content
Five Facts about spinal muscular atrophy
1 Spinal muscular atrophy (SMA) is a genetic disease involving the loss of motor neurons …
Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases
Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) …
Spike in searches relating to spinal muscular atrophy following Jesy Nelson disclosure
New research from the Centre for Surgery has shown a significant rise in Google searches …
